Trivarx Limited · ASX:TRI
Trivarx — JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026)
17 slides from Trivarx's conference presentation, Jun 25, 2026
Slide 1: ASX Announcement: Investor presentation, Boom of the Biotech II
ASX ANNOUNCEMENT 25 June 2026 Investor presentation: JP Equity Partners' 'Boom of the Biotech II' Investor Briefing Perth, Australia, and Minneapolis, USA: TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to provide the following investor presentation to be presented by Chief Executive Officer,
Slide 2: Stabl-Im: A potential new approach to imaging and therapy in CNS oncology
For personal use only STABL-IM: A POTENTIAL NEW APPROACH TO IMAGING AND THERAPY IN CNS ONCOLOGY Investor Presentation – June 2026 Dr Danielle Meyrick ASX: TRI
Slide 3: Forward-looking statements
Forward-looking statements The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slide
Slide 4: CEO introduction and background - Dr Danielle Meyrick
CEO introduction and background - Dr Danielle Meyrick MULTI-DIMENSIONAL TRACK RECORD ➢ Dual-trained medical doctor and PhD-qualified radiopharmaceutical chemist For personal use only ➢ Experience spanning multiple sectors, with a consistent focus on translating intricate science into practically exe
Slide 5: TrivarX operating principles and execution focus
TrivarX operating principles and execution focus BUILD AND MAINTAIN MOMENTUM IMMEDIATE EXECUTION FOCUS ➢ Convert scientific opportunity into milestone- For personal use only ➢ Prioritise evidence- and science-led driven development program development • Investigational product supply ➢ Apply ‘patien
Slide 6: Stabl-Im: A potential transformation in the imaging and therapy of brain and other cancers
Stabl-Im: A potential transformation in the imaging and therapy of brain and other cancers ➢ Concept developed by Nucleics Pty Ltd and acquired in-house at TrivarX For personal use only December 2025 ➢ Technology has the potential to enable improved imaging and monitoring of brain cancers with the u
Slide 7: Scientific and strategic review: imaging concept to broader CNS oncology program
Scientific and strategic review: imaging concept to broader CNS oncology program For personal use only 1 Original focus Broader review Expanded application Near-term actions Brain metastases Reveals potential CNS Evaluate across Prioritise the lead imaging and oncology relevance imaging and potentia
Slide 8: An opportunity in a major market
An opportunity in a major market Innovative technology to pursue significant opportunities in the diagnostic imaging and neuro-oncologic markets MARKET OVERVIEW KEY DRIVERS ➢ Global medical imaging market ~US$82bn+¹, with MRI a high-value, fast- For personal use only growing segment ➢ Increasing can
Slide 9: Current standard of care
Current standard of care • Contrast-enhanced MRI is the reference standard for brain metastases detection and monitoring • A PET (positron emission tomography) scan may be used as an adjunct to differentiate progression from treatment effect CONTRAST-ENHANCED MRI STABL-Im MRI PET SCAN For personal u
Slide 10: Magnetic Resonance Imaging (MRI) overview
Magnetic Resonance Imaging (MRI) overview MRI is an imaging technique that uses high magnetic fields and radio waves to visualise soft tissue. It has many applications but inherent detection limitations THE MRI PROCESS AND THE HYDROGEN ENVIRONMENT For personal use only ➢ MRI gives information about
Slide 11: Stabl-Im – Stable Isotope Imaging
Stabl-Im – Stable Isotope Imaging Stabl-Im uses stable isotope labelling to identify rapidly dividing cancer cells using routinely used MRI hardware – providing a radiation-free, non-invasive detection and response-monitoring approach For personal use only Cell Uptake Metabolism MRI Detection Admini
Slide 12: Safety in humans
Safety in humans Previous pre-clinical and clinical studies demonstrate that Stabl-Im is safe in animals and humans, providing a strong foundation for the planned plasma enrichment and clinical feasibility trial For personal use only SAFETY ASPECTS ➢ Stabl-Im is demonstrably safe in animals up to ~2
Slide 13: Clinical and regulatory pathway
Clinical and regulatory pathway Near term program to prioritise the strongest CNS oncology development pathway across imaging and potential therapeutic applications ➢ Clear early phase regulatory approach: Stabl-Im is a stable, non-radioactive investigational product that is readily For personal use
Slide 14: Stabl-Im presents several potential advantages
Stabl-Im presents several potential advantages Actionable information with the potential to change clinical practice, combined with an accelerated regulatory pathway and a disciplined clinical development strategy, provides considerable upside 1 2 3 For personal use only Non-radioactive MRI-based de
Slide 15: Multiple near-term value drivers
Multiple near-term value drivers Defined work programs underpin potential for significant near-term value creation Activity Timing For personal use only Key appointments to strengthen management team Q2 CY26 Completion of pre-clinical trial design requirements July 2026 Commencement and completion o
Slide 16: Contact
For personal use only CONTACT TrivarX Limited (ASX: TRI) E: Investors@trivarx.com A: Suite 1.01, 117 Camberwell Road, Hawthorn East VIC 3123 Danielle Meyrick – Chief Executive Officer: T: +61 419 610 137 E: Danielle@trivarx.com Henry Jordan – Six Degrees Investor Relations T: +61 431 271 538 E: Henr
Slide 17: References
References 1. https://www.mordorintelligence.com/industry- reports/medical-imaging-market For personal use only 2. https://www.mordorintelligence.com/industry- reports/global-mri-market-industry 3. https://www.marketreportsworld.com/market- reports/mri-market-14720951 4. https://www.abta.org/about-b
TrivarX — JP Equity Partners 'Boom of the Biotech II' Investor Briefing (June 2026) on 6ix